Trials / Completed
CompletedNCT01198769
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
Immunogenicity, Reactogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 12 Weeks
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess immunogenicity and safety of Rotarix TM when administered in healthy Taiwanese infants (aged 6 to 12 weeks at the time of first vaccination) who received Hepatitis B immunoglobulin after birth.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rotarix TM | Oral, 2 doses |
Timeline
- Start date
- 2010-11-11
- Primary completion
- 2011-04-18
- Completion
- 2011-04-18
- First posted
- 2010-09-10
- Last updated
- 2018-08-20
- Results posted
- 2012-04-17
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01198769. Inclusion in this directory is not an endorsement.